News

Medtronic has completed its acquisition of Scientia Vascular, a privately owned medical device company headquartered in Salt Lake City. The deal is valued at $550 million, subject to customary adjustments, and may include additional undisclosed earn-out and milestone payments following completion.

Scientia has developed a portfolio of advanced access technologies designed to simplify procedures and improve access for physicians treating complex neurovascular conditions. Its range of guidewires and catheters complements Medtronic’s existing neurovascular offering and is expected to enhance the company’s ability to support clinicians throughout the entire procedural pathway.

“Since its founding, Scientia has been driven by a commitment to improving patients’ lives and supporting the physicians who care for them,” said Rick Randall, CEO of Scientia. “Joining Medtronic is an exciting next step for our team, as their Mission closely aligns with the values that have guided Scientia from the beginning. With Medtronic’s global scale, we look forward to bringing this technology to more physicians and reaching more patients around the world.”

“The addition of Scientia’s access technologies strengthens our ability to simplify complex neurovascular procedures and support physicians with more seamless solutions,” said Linnea Burman, senior vice president and president of Medtronic’s Neurovascular business, part of the Neuroscience Portfolio at Medtronic. “By bringing together highly complementary technologies, we are building a more integrated platform that will help advance the future of neurovascular care and enable physicians to treat more patients with greater efficiency and confidence.”

In stroke care, time is critical. Every second that blood flow to the brain is restricted results in the loss of millions of brain cells. Stroke is currently the third leading cause of death and the leading cause of disability worldwide.

The cerebral vasculature is particularly complex and tortuous compared with blood vessels in many other areas of the body, making it challenging for physicians to reach the location of an occlusion or aneurysm. Difficult vascular access can delay treatment and affect procedural outcomes.

Scientia’s innovative access platform has been developed to overcome these challenges by enhancing navigability through complex anatomy and streamlining neurovascular procedures. By providing quicker and more dependable access, the technologies can help improve procedural efficiency.

The acquisition underscores Medtronic’s ongoing strategy of pursuing targeted transactions that reinforce its leadership in key business areas. The company remains focused on investing in high-growth opportunities that complement its portfolio and deliver additional value to physicians and healthcare providers.

© Medtronic